| Code | CSB-RA624104MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to CT-P52, designed to specifically target interleukin-17A (IL-17A), a pro-inflammatory cytokine central to immune-mediated inflammatory responses. IL-17A is primarily produced by Th17 cells and plays a critical role in host defense against extracellular pathogens, but its dysregulation drives pathological inflammation in numerous autoimmune and inflammatory conditions. Elevated IL-17A levels are implicated in psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease, where it promotes neutrophil recruitment, induces pro-inflammatory mediator production, and contributes to tissue damage and chronic inflammation.
CT-P52 is a biosimilar reference antibody to secukinumab, a fully humanized IgG1 monoclonal antibody that neutralizes IL-17A by preventing its interaction with the IL-17 receptor. This biosimilar antibody serves as a valuable research tool for investigating IL-17A-mediated signaling pathways, exploring inflammatory disease mechanisms, evaluating therapeutic intervention strategies, and conducting preclinical studies in immunology and inflammation research. It enables researchers to study the biological consequences of IL-17A neutralization in various experimental models.
There are currently no reviews for this product.